Adrian Veres
About Adrian Veres
Adrian Veres is the Chief Scientific Officer and Co-Founder of Dyno Therapeutics, with a background in systems biology and gene therapy research.
Chief Scientific Officer at Dyno Therapeutics
Adrian Veres is the Chief Scientific Officer (CSO) at Dyno Therapeutics, located in Watertown, Massachusetts, United States. In this role, he spearheads the scientific agenda of the company, driving innovation and overseeing research and development initiatives. His work focuses on advancing gene therapy technologies, a testament to his extensive expertise in the field.
Co-Founder of Dyno Therapeutics
Adrian Veres is also a co-founder of Dyno Therapeutics. This dual role highlights his integral position within the company, not only directing scientific endeavors but also shaping the company's strategic vision. Under his leadership, Dyno Therapeutics has secured significant funding for its groundbreaking research projects.
Previous Role as Postdoctoral Research Fellow at Harvard University
Adrian Veres previously served as a Postdoctoral Research Fellow at Harvard University from 2021 to 2023. During his tenure, he contributed significantly to the field of gene therapy and systems biology. His research focused on in vitro differentiation of pancreatic beta cells and the application of single-cell RNA sequencing, in collaboration with Prof. Douglas Melton and Semma Therapeutics.
Educational Background
Adrian Veres has a robust academic background. He earned a Doctor of Philosophy (PhD) in Systems Biology from the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences, completing his studies in 2019. Additionally, he holds a Doctor of Medicine (MD) from the prestigious Harvard-MIT Health Sciences and Technology program, completed in 2020. He also graduated summa cum laude with a Bachelor's degree in Chemistry & Physics from Harvard University in 2012.
Research Contributions and Publications
Adrian Veres has co-authored several research papers in the field of gene therapy, sharing his findings and insights with the scientific community. His extensive experience in systems biology has been pivotal in advancing the understanding of gene therapy technologies. His academic work includes studies on the evolutionary dynamics of antibiotic resistance in microbes and the in vitro differentiation of beta cells for diabetes treatment.